Herceptin, Trastuzumab Newswire (Page 10)

Herceptin, Trastuzumab Newswire (Page 10)

Comprehensive Real-Time News Feed for Herceptin, Trastuzumab (generic). (Page 10)

Results 181 - 200 of 479 in Herceptin, Trastuzumab (generic)

  1. Theradiag: 2015 Revenues: Very Strong Sales Growth of Lisa Tracker KitsRead the original story

    Feb 8, 2016 | Business Wire

    THERADIAG , a company specializing in theranostics and in vitro diagnostics, announced today its consolidated full-year revenues for 2015. Theradiag generated consolidated revenues of 7.6 million in 2015, an increase of 6%, with an increase of 11% in the second half.

    Comment?

  2. Biocon set to seek USFDA approval for biosimilarsRead the original story w/Photo

    Feb 7, 2016 | The Indian Express

    India's largest biopharma company, Biocon, is gearing up to enter the regulated markets of the US and the UK with a portfolio of biosimilars. The company is in advanced stages of completing global phase-III trials for four out of nine biosimilar programmes in partnership with Mylan, a US-based drug maker.

    Comment?

  3. Immunomedics's Breast Cancer Drug Wins Breakthrough Tag from the FDARead the original story

    Feb 4, 2016 | BioSpace

    Immunomedics, Inc. , today announced that its lead investigational antibody-drug conjugate, sacituzumab govitecan, or IMMU-132, has received Breakthrough Therapy Designation from the FDA for the treatment of patients with triple-negative breast cancer who have failed at least 2 prior therapies for metastatic disease. The Breakthrough Therapy Designation was supported by a Phase 2 study in patients with metastatic TNBC who had received a median of 5 prior therapies .

    Comment?

  4. Haemophilia drugs set to cost moreRead the original story w/Photo

    Feb 6, 2016 | The Telegraph

    New Delhi, Feb. 6: Patients who rely exclusively on imported versions of certain medicines against cancer, diabetes and HIV, among other illnesses, may need to pay higher prices after a government move to boost sales of domestic drugs. A notification issued by the Central Board of Excise and Customs withdrawing the exemption of basic customs duty on 76 drugs is likely to increase the retail prices of imported versions of these medicines, industry analysts and patients' rights activists have said.

    Comment?

  5. Breast cancer survivors could be vulnerable to common viral and bacterial infectionsRead the original story w/Photo

    Jan 26, 2016 | PhysOrg Weblog

    Breast cancer survivors treated with chemotherapy could be lacking sufficient antibodies to protect against common illnesses, as chemotherapy reduces the body's immune response, according to research published in the open access journal Breast Cancer Research . This work raises the possibility that these survivors could benefit from additional post-treatment monitoring.

    Comment?

  6. Molecular targeted photoimmunotherapy for HER2-positive human gastric ...Read the original story

    Jan 24, 2016 | BioMed Central

    NCI-N87 cells, HER2-positive human gastric cancer cells, were used for the experiments. Trastuzumab, a monoclonal antibody directed against HER2, was conjugated to IR700.

    Comment?

  7. Research AwardsRead the original story

    Feb 1, 2010 | Vox of Dartmouth

    Dartmouth researchers were awarded $4.7 million during November, including $1.2 million in new and competing awards.

    Comment?

  8. Biocon Q3 net up 13% at Rs 103 croreRead the original story w/Photo

    Jan 22, 2016 | Express India

    Biotechnology major Biocon has reported 13.31 per cent rise in consolidated net profit of Rs 103 crore for the third quarter ended December 31, 2015-16. Biotechnology major Biocon has reported 13.31 per cent rise in consolidated net profit of Rs 103 crore for the third quarter ended December 31, 2015-16.

    Comment?

  9. Biocon net up 13 percent in Q3Read the original story

    Jan 21, 2016 | Newkerala.com

    Bengaluru, Jan 22 : Leading biotechnology firm Biocon Ltd on Friday reported Rs.103-crore net profit for third quarter of this fiscal , posting 13 percent year-on-year profit from Rs.91 crore year ago. The city-based pharma major said revenue from sales rose nine percent YoY to Rs.828 crore for the quarter under review from Rs.761 crore year ago.

    Comment?

  10. Antibody-drug conjugates-an emerging class of cancer treatmentRead the original story

    Jan 7, 2016 | British Journal of Cancer

    New linker technology associated with novel highly potent cytotoxic payloads has permitted the development of more effective and safe ADCs. In recent years, two ADCs have been licensed, T-DM1 and brentuximab vedotin, and are already establishing their place in cancer treatment.

    Comment?

  11. In This IssueRead the original story w/Photo

    Dec 22, 2015 | Molecular Therapy

    A universal method for subcellular targeting of bioactive molecules to lysosomes could be useful for the development of therapeutics. Moody et al. report that a method of receptor crosslinking can trigger endocytosis and redirect trafficking of receptor:cargo complexes from their expected route to lysosomes.

    Comment?

  12. BIOCAD Announces the First Trastuzumab B ...Read the original story

    Jan 20, 2016 | The Financial Mirror

    The trastuzumab biosimilar, to be marketed under the trade name HERtiCADa , is the first trastuzumab biosimilar to receive authorization from the Russian regulatory body. The market authorization of the trastuzumab biosimilar followed the results of a randomized multicenter clinical study comparing the pharmacokinetics, immunogenicity, safety, and efficacy of BCD-022 to the innovator Herceptin .

    Comment?

  13. View Press ReleaseRead the original story

    Jan 20, 2016 | Business Wire

    The market authorization of the trastuzumab biosimilar followed the results of a randomized multicenter clinical study comparing the pharmacokinetics, immunogenicity, safety, and efficacy of BCD-022 to the innovator Herceptin . BIOCAD started development of trastuzumab biosimilar in 2010 in the context of a federal innovative project that was approved by the Presidential Commission on Modernization and Technological Advancement simultaneously with other two biosimilars of rituximab and bevacizumab, which were also registered in Russia in 2014 and 2015, respectively.

    Comment?

  14. Correction [Corrections]Read the original story

    Jan 18, 2016 | Circulation

    In the article by Witteles and Bosch, "Myocardial Protection During Cardiotoxic Chemotherapy", which published in the November 10, 2015 issue of the journal , several corrections are needed: On p 1838, the reference at the end of the first paragraph under the subheading "Trastuzumab" should be 9, not 35. On p 1838, the last sentence in the second paragraph under the subheading "Biomarkers" should read: "Troponin rises almost always occurred prior to trastuzumab invitation or very early during trastuzumab therapy, supportive of the theory that troponin rises mainly reflected anthracycline effects rather than direct effects from the trastuzumab itself.

    Comment?

  15. Companion Diagnostics EvolveRead the original story w/Photo

    Jan 18, 2016 | Advance

    Out of seven billion people on this earth, no two people are the same. Companion diagnostics providers argue their medicines shouldn't be the same either.

    Comment?

  16. Cancer Treatment and Heart-Related Side EffectsRead the original story w/Photo

    Jan 13, 2016 | CBS Local

    CBS 3 CBS 3 joined forces with the most trusted local CBS RADIO stations in Philadelphia to give you the best Philly has to offer. CBS 3 is part of CBS Television Stations, a division of CBS [] KYW Newsradio 1060 Welcome to KYW Newsradio 1060 on CBSPhilly.com.

    Comment?

  17. Oncothyreon Appoints Christopher Henney, Ph.D., D.Sc. as Interim CEO...Read the original story w/Photo

    Jan 11, 2016 | GlobeNewswire

    Oncothyreon Inc. , a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products that can improve the lives and outcomes of patients with cancer, today announced that Robert L. Kirkman, M.D., has retired as president and CEO and as a member of the Board of Directors, effective January 11, 2016. Oncothyreon's Board of Directors has appointed Christopher S. Henney, Ph.D., D.Sc., the company's chairman, to serve as interim CEO while the company conducts a comprehensive search for a new CEO.

    Comment?

  18. Mylan to collaborate on biosimilar productsRead the original story w/Photo

    Jan 8, 2016 | O-R Online

    Mylan N.V. said Friday it has entered into an exclusive global collaboration agreement with Momenta Pharmaceuticals, Inc. to develop, manufacture and commercialize six of Momenta's current biosimilar candidates, including Momenta's biosimilar candidate, Orencia.

    Comment?

  19. Mylan, Momenta in Exclusive Global Biosimilar AllianceRead the original story w/Photo

    Jan 8, 2016 | Contract Pharma Breaking News

    Mylan has entered into an exclusive global collaboration agreement with Momenta Pharmaceuticals to develop, manufacture and commercialize six of Momenta's biosimilar candidates, including abatacept , which had $1.7 billion in sales in 2014. Momenta will receive $45 million up front and as much as $200 million in milestone-related payments, with each company sharing the costs and profits for the products.

    Comment?

  20. Effect of trastuzumab interchain disulfide bond cleavage on Fc{gamma} ...Read the original story

    Jan 7, 2016 | Journal of Biochemistry

    The Fc domain of human IgG1 binds to FcI3 receptors to induce effector functions such as phagocytosis. There are four interchain disulfide bonds between the H and L chains.

    Comment?